| Analysts were expecting Alkermes, Inc. (ALKS) [Chart - News - Analysis] to report earnings of $-0.09 for last quarter, and ALKS met expectations with actual earnings of $-0.09---in line the consensus estimate. ALKS also issued earnings guidance for next quarter that is below current analyst expectations. If you compare last quarter's earnings to the $0.02 the company made per share during the same quarter a year ago, you can see that ALKS’s earnings are down this year. Check this out (it's free!): Stocks You Should Be Watching Right Now; How to Make Good Picks
| | | | | |
-
Essential Reading for Traders
-
| | |
| | | | | | | | Also, if you compare ALKS's 37.00% projected earnings-per-share (EPS) growth rate for the next five years with the projected EPS growth rate of 14.10% for the Drug Delivery industry as a whole during that same time frame, you can see that analysts expect ALKS to outperform the industry in the future---which is a good sign for the stock. Drilling down a little deeper into the Drug Delivery industry, you can see how analysts believe ALKS will stack up against some of the other stocks in the industry, like Acura Pharmaceuticals Inc. (ACUR) [Chart - News - Analysis] and Biovail Corporation (BVF) [Chart - News - Analysis], in the future. Analysts believe ACUR's earnings are going to grow at a rate of 0.00% while BVF's earnings are going to grow at a rate of 7.50%. Earnings season can be a volatile time in the stock market. Check out these videos and articles to be better prepared to take advantage of the large price moves that tend to accompany earnings announcements. - Earnings Season is Here - Find Out How to Trade It - Using Options to Trade Earnings - Understanding Stock Analyst Research and Recommendations More...
Keep up with us:
| 
